Bris­tol My­ers, Ab­b­Vie drugs shake up first-line pre­scrib­ing among gas­troen­terol­o­gists — re­port

Bris­tol My­ers Squibb and Ab­b­Vie are chang­ing up the in­flam­ma­to­ry bow­el dis­ease (IBD) mar­ket with gas­troen­terol­o­gists, thanks to new­er-to-mar­ket drugs Zeposia and Skyrizi, re­spec­tive­ly. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER